​

Funding Round

Series B - Homology Medicines

Series B - Homology Medicines

Investment Firm

Overview

Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.

Announced Date

Aug 01, 2017

Funding Type

Series B

Highlights

Location

United States, North America

Social

Investor Lead

Deerfield

Deerfield

Deerfield is a debt and early_stage_venture firm.

Participant Investors

12

Investor Name
Participant InvestorNovartis
Participant InvestorARCH Venture Partners
Participant InvestorOUP (Osage University Partners)
Participant InvestorVivo Capital
Participant InvestorFidelity

Round Details and Background

Homology Medicines raised $83500000 on 2017-08-01 in Series B

Homology Medicines is a genetic medicines company dedicated to transforming the lives of patients suffering from rare genetic diseases.

Company Funding History

3

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Nov 09, 2020
Post-IPO Equity - Homology Medicines
1-60.0M
Aug 01, 2017
Series B - Homology Medicines
13-83.5M
May 02, 2016
Series A - Homology Medicines
5-43.5M

Recent Activity

There is no recent news or activity for this profile.